Pfizer begins clinical trial for Omicron-targeted COVID vaccine

Sign up for our daily briefingMake your busy days simpler with the Axios AM and PM newsletters. Catch up on what’s new and why it matters in just 5 minutes.Catch up on the day’s biggest business storiesSubscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.Sign up for Axios Pro RataDive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.Sports news worthy of your timeBinge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.Tech news worthy of your timeGet our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.Get the inside storiesGet an insider’s guide to the new White House with Axios Sneak Peek. Sign up for free.Catch up on coronavirus stories and special reports, curated by Mike Allen everydayCatch up on coronavirus stories and special reports, curated by Mike Allen everydayWant a daily digest of the top Denver news?Get a daily digest of the most important stories affecting your hometown with Axios DenverWant a daily digest of the top Des Moines news?Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.Want a daily digest of the top Twin Cities news?Get a daily digest of the most important stories affecting your hometown with Axios Twin CitiesWant a daily digest of the top Tampa Bay news?Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.Want a daily digest of the top Charlotte news?Get a daily digest of the most important stories affecting your hometown with Axios CharlotteWant a daily digest of the top Nashville news?Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.Want a daily digest of the top Columbus news?Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.Want a daily digest of the top Dallas news?Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.Want a daily digest of the top Austin news?Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.Want a daily digest of the top Atlanta news?Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.Want a daily digest of the top Philadelphia news?Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.Want a daily digest of the top Chicago news?Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.Sign up for Axios NW ArkansasStay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reportersWant a daily digest of the top DC news?Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.A health worker in Palestine preparing a dose of the Pfizer-BioNTech’s coronavirus vaccine on Jan. 24. Photo: Majdi Fathi/NurPhoto via Getty ImagesPfizer and BioNTech announced Tuesday that they have started clinical trials for a reformulated vaccine to protect against the Omicron coronavirus variant.Why it matters: The rise of the Omicron variant has forced vaccine makers to reassess the effectiveness of their vaccines.Data has shown that booster doses of the Pfizer-BioNTech vaccine were effective at neutralizing Omicron. But just two doses of it were far less effective against the new variant.What they’re saying: “While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,” said Kathrin Jansen, Pfizer’s head of vaccine research and development in a statement.The big picture: The trial will involve up to 1,420 participants across the three cohorts.One of the groups will receive two doses of the companies’ COVID vaccine, another will receive two doses and a booster dose of their vaccine, while the last will receive the Omicron-based vaccine.Pfizer and BioNTech said it plans to manufacture four billion doses of the vaccine in 2022 and said that would not change even if an adapted vaccine is required.Go deeper: The end of the Omicron wave is in sight